|
One of Moonshot at NACET’s first business incubator and accelerator clients, Symple Surgical, Inc. (SSI), is graduating from the entrepreneurial program and relocating to Flagstaff Airport Airpark after securing significant grants and angel investment funds.Continue reading
The move would enable the organizations to meet a demand for clinical cell therapies that is expected to grow 42 percent annually over the next decadeContinue reading
NIH grant will allow Taben Hale, PhD, to study cardiac fibroblasts.
A University of Arizona College of Medicine – Phoenix researcher has received a $393,493 grant from the National Institutes of Health to further her research in reducing the risk of heart failure in patients with high blood pressure.Continue reading
The Huntington’s Disease Regulatory Science Consortium (HD-RSC), launched in March 2018 by the Critical Path Institute (C-Path) and CHDI Foundation, today, along with the Clinical Data Interchange Standards Consortium (CDISC), announce the open availability of a newly developed Huntington’s Disease Therapeutic Area User Guide
Continue reading
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Maureen T. Cronin, Ph.D., as the Company’s Chief Scientific Officer and Senior Vice President as of November 16, 2018. Dr. Cronin is a veteran biotechnology, translational science and diagnostic executive.Continue reading
TUCSON, Ariz. – Two University of Arizona College of Medicine – Tucson surgery professors are among 91 surgeons from seven nations selected to the new American College of Surgeons (ACS) Academy of Master Surgeon Educators.
The new Master Surgeon Educators are UA Department of Surgery Chair Leigh Neumayer, MD, MS, FACS, and Professor James H. McClenathan, MD, FACS .Continue reading
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.
The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.